BR112022025613A2 - Novo inibidor de secreção de ácido e uso do mesmo - Google Patents

Novo inibidor de secreção de ácido e uso do mesmo

Info

Publication number
BR112022025613A2
BR112022025613A2 BR112022025613A BR112022025613A BR112022025613A2 BR 112022025613 A2 BR112022025613 A2 BR 112022025613A2 BR 112022025613 A BR112022025613 A BR 112022025613A BR 112022025613 A BR112022025613 A BR 112022025613A BR 112022025613 A2 BR112022025613 A2 BR 112022025613A2
Authority
BR
Brazil
Prior art keywords
acid secretion
new acid
secretion inhibitors
new
new compound
Prior art date
Application number
BR112022025613A
Other languages
English (en)
Inventor
Hong Chul Yoon
Joon Tae Park
Jung Woo Lee
Kyung Mi An
A Rang Im
Woo Jin Jeon
Jae Ho Heo
Chang Hee Hong
Jung Eun Park
Te Ik Sohn
Da Hae Hong
Jung Ho Kim
Jae Eui Shin
Yeong Ran Yoo
Min Whan Chang
Su Yeon Kang
In Gyu Je
Joo Yun Lee
Yoon Sung Song
Original Assignee
Ildong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ildong Pharmaceutical Co Ltd filed Critical Ildong Pharmaceutical Co Ltd
Publication of BR112022025613A2 publication Critical patent/BR112022025613A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

NOVO INIBIDOR DE SECREÇÃO DE ÁCIDO E USO DO MESMO apresenta invenção que fornece um novo composto representado pela Fórmula Química 2, ou um sal farmaceuticamente aceitável do mesmo. O novo composto de acordo com a presente invenção exibe um excelente efeito inibidor da secreção de ácido.
BR112022025613A 2020-06-17 2021-06-16 Novo inibidor de secreção de ácido e uso do mesmo BR112022025613A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200073900 2020-06-17
PCT/KR2021/007572 WO2021256861A1 (ko) 2020-06-17 2021-06-16 신규한 산 분비 억제제 및 이의 용도

Publications (1)

Publication Number Publication Date
BR112022025613A2 true BR112022025613A2 (pt) 2023-01-17

Family

ID=79176045

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025613A BR112022025613A2 (pt) 2020-06-17 2021-06-16 Novo inibidor de secreção de ácido e uso do mesmo

Country Status (16)

Country Link
US (2) US11767311B2 (pt)
EP (1) EP4148050A4 (pt)
JP (1) JP7404561B2 (pt)
KR (2) KR20210156235A (pt)
CN (1) CN115884968B (pt)
AU (1) AU2021293694B2 (pt)
BR (1) BR112022025613A2 (pt)
CA (1) CA3182882A1 (pt)
CL (1) CL2022003601A1 (pt)
CO (1) CO2023000396A2 (pt)
DO (1) DOP2022000291A (pt)
EC (1) ECSP23002606A (pt)
MX (1) MX2022016515A (pt)
PE (1) PE20231652A1 (pt)
TW (2) TWI839161B (pt)
WO (1) WO2021256861A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115884968B (zh) 2020-06-17 2024-06-21 日东制药株式会社 新型酸分泌抑制剂及其用途
CN118401510A (zh) * 2021-12-15 2024-07-26 日东制药株式会社 1-磺酰基吡咯衍生物的新颖盐类、其制备方法及包含其的药物组合物
WO2023113474A1 (ko) * 2021-12-15 2023-06-22 일동제약(주) 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
KR20230102353A (ko) * 2021-12-30 2023-07-07 주식회사 대웅제약 삼중음성유방암의 예방 또는 치료용 약학적 조성물
CN114539219A (zh) * 2022-03-17 2022-05-27 日照正济药业有限公司 一种富马酸伏诺拉生的制备方法
WO2023211843A1 (en) * 2022-04-25 2023-11-02 Daewoong Pharmaceutical Co., Ltd. Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions
TW202411216A (zh) * 2022-05-23 2024-03-16 南韓商日東製藥股份有限公司 ６－甲氧基吡啶－３－基衍生物之製造方法
WO2023229322A1 (ko) * 2022-05-23 2023-11-30 일동제약(주) 6-메톡시피리딘-3-일 유도체의 제조방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE437642T1 (de) * 2002-06-14 2009-08-15 Takeda Pharmaceutical Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
ES2402362T3 (es) * 2004-09-30 2013-05-03 Takeda Pharmaceutical Company Limited Inhibidores de la bomba de protones
PE20070540A1 (es) * 2005-08-30 2007-06-26 Takeda Pharmaceutical Derivados de pirrol como inhibidores de la secrecion acida
US7994205B2 (en) * 2006-03-31 2011-08-09 Takeda Pharmaceutical Company Limited Aryl-or heteroaryl-sulfonyl compounds as acid secretion inhibitors
US8933105B2 (en) * 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
EP2318390B1 (en) * 2008-08-27 2013-05-01 Takeda Pharmaceutical Company Limited Pyrrole compounds
PE20120618A1 (es) * 2009-03-26 2012-06-05 Takeda Pharmaceutical Compuestos de pirazol como inhibidores de la bomba de protones
NZ703528A (en) * 2012-06-27 2016-08-26 Takeda Pharmaceutical Liquid preparations of amines and organic acids stabilized by salts
MY176887A (en) * 2013-02-28 2020-08-25 Takeda Pharmaceuticals Co Method for producing sulfonyl chloride compound
CN105693693A (zh) * 2014-11-27 2016-06-22 江苏柯菲平医药股份有限公司 一种吡咯类胃酸分泌和抑制剂化合物盐的制备
CN105985278A (zh) * 2015-01-27 2016-10-05 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
KR101613245B1 (ko) * 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN106432191A (zh) * 2015-08-10 2017-02-22 陕西合成药业股份有限公司 一种新的吡咯类衍生物、其制备方法及其在医药上的应用
KR20170113040A (ko) * 2016-03-25 2017-10-12 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염
US10912769B2 (en) * 2016-09-29 2021-02-09 Jiangsu Jibeier Pharmaceutical Co. Ltd. 1-[(pyridin-3-yl-sulfonyl)-1H-pyrrol-3-yl] methanamine derivative and pharmaceutical composition and use thereof
WO2019013310A1 (en) 2017-07-10 2019-01-17 Takeda Pharmaceutical Company Limited PREPARATION COMPRISING VONOPRAZAN
CN110396080B (zh) * 2018-04-24 2022-07-08 广东东阳光药业有限公司 一种富马酸沃诺拉赞代谢物及其氘代物的制备方法
CN108558831B (zh) * 2018-06-08 2021-07-27 上海璃道医药科技有限公司 取代吡咯-4-烷基胺类化合物及其用途
CN115884968B (zh) 2020-06-17 2024-06-21 日东制药株式会社 新型酸分泌抑制剂及其用途
CN111943932B (zh) * 2020-08-06 2023-07-14 四川国康药业有限公司 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途

Also Published As

Publication number Publication date
EP4148050A4 (en) 2023-10-25
TWI839161B (zh) 2024-04-11
CN115884968A (zh) 2023-03-31
CA3182882A1 (en) 2021-12-23
ECSP23002606A (es) 2023-03-31
AU2021293694A1 (en) 2023-01-19
TWI797645B (zh) 2023-04-01
KR20210156235A (ko) 2021-12-24
AU2021293694B2 (en) 2023-12-21
DOP2022000291A (es) 2023-01-15
EP4148050A1 (en) 2023-03-15
KR102432523B1 (ko) 2022-08-16
CO2023000396A2 (es) 2023-02-27
TW202214588A (zh) 2022-04-16
JP7404561B2 (ja) 2023-12-25
JP2023524172A (ja) 2023-06-08
PE20231652A1 (es) 2023-10-17
WO2021256861A1 (ko) 2021-12-23
TW202325702A (zh) 2023-07-01
CN115884968B (zh) 2024-06-21
CL2022003601A1 (es) 2023-07-07
US20230192650A1 (en) 2023-06-22
US11767311B2 (en) 2023-09-26
MX2022016515A (es) 2023-01-30
KR20210156234A (ko) 2021-12-24
US20230373954A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
BR112022025613A2 (pt) Novo inibidor de secreção de ácido e uso do mesmo
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
CR20220351A (es) Inhibidores de proteínas kras mutantes
UY38186A (es) Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida
BR112019024785A2 (pt) composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso
BR112022012585A2 (pt) Inibidores de formas mutantes de egfr
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
BR112020016020A8 (pt) Inibidor de atr e aplicação do mesmo
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
CO2021008681A2 (es) Inhibidor de 15-pgdh
AR126251A1 (es) Inhibidores de cdk2
BR112021023927A2 (pt) Composto, e, composição farmacêutica
CO2021001849A2 (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende
BR112022013849A2 (pt) Novo derivado de pirazol
CO2022000270A2 (es) Inhibidores de enzimas
BR112022012368A2 (pt) Composto, e, composição farmacêutica para o tratamento de doenças associadas a diacilglicerol aciltransferase 2
PH12021550258A1 (en) Cdk8/19 inhibitors
WO2021002986A3 (en) Bax inhibitors and uses thereof
BR112019015428A2 (pt) Derivativos de pirrolotriazina como inibidor de quinase
BR112023003807A2 (pt) Derivado de amina
BR112022007729A2 (pt) Polipeptídeo tendo efeito mmp2-inibidor
MX2023015126A (es) Compuestos y metodos para tratar la hiperpotasemia.